Cover Image
市場調查報告書

中外製藥的產品平台分析

Chugai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 251653
出版日期 內容資訊 英文 119 Pages
訂單完成後即時交付
價格
Back to Top
中外製藥的產品平台分析 Chugai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016
出版日期: 2016年07月27日 內容資訊: 英文 119 Pages
簡介

中外製藥是總公司設在日本的製藥企業,進行製藥產品的開發及商品化。對象疾病領域是癌症、骨頭及關節的疾病、腎臟疾病等。該公司利用生物製藥和分子標靶藥物相關先進技術,進行藥物研發及藥物候補物質的開發。

本報告提供中外製藥的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

中外製藥 基本資料

  • 中外製藥 概要
  • 主要資訊
  • 企業資料

中外製藥 :R&D概要

  • 主要的治療範圍

中外製藥 :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

中外製藥 :開發中產品概況

  • 後期階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

中外製藥:藥物簡介

  • ibandronate sodium
  • atezolizumab
  • gantenerumab
  • lebrikizumab
  • obinutuzumab
  • pertuzumab
  • SA-237
  • tocilizumab
  • trastuzumab emtansine
  • basimglurant
  • bevacizumab
  • codrituzumab
  • nemolizumab
  • pictilisib
  • polatuzumab vedotin
  • RG-1577
  • RG-1662
  • RG-7304
  • taselisib
  • Antibody for Colorectal Cancer
  • CH-5036249
  • CH-5164840
  • CH-5449302
  • CH-5451098
  • cVE-199
  • maxacalcitol
  • Monoclonal Antibody for Hepatitis C
  • NA-255
  • PCO-371

中外製藥 :開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

中外製藥 :最新的開發平台資訊

中外製藥 :開發暫停中的計劃

中外製藥 :開發中止的開發中產品

  • 開發中止的開發中產品簡介

中外製藥 :企業理念

中外製藥 :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08098CDB

Summary

Global Markets Direct's, 'Chugai Pharmaceutical Co., Ltd. - Product Pipeline Review, 2016', provides an overview of the Chugai Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Chugai Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Chugai Pharmaceutical Co., Ltd.
  • The report provides overview of Chugai Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Chugai Pharmaceutical Co., Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Chugai Pharmaceutical Co., Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Chugai Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chugai Pharmaceutical Co., Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chugai Pharmaceutical Co., Ltd.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Chugai Pharmaceutical Co., Ltd. Snapshot
    • Chugai Pharmaceutical Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Chugai Pharmaceutical Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Chugai Pharmaceutical Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Chugai Pharmaceutical Co., Ltd. - Pipeline Products Glance
    • Chugai Pharmaceutical Co., Ltd. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Chugai Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Chugai Pharmaceutical Co., Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Chugai Pharmaceutical Co., Ltd. - Drug Profiles
    • atezolizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bevacizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eldecalcitol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • gantenerumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lebrikizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • obinutuzumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SA-237
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tocilizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • codrituzumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nemolizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • basmisanil
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EOS-789
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PCO-371
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • polatuzumab vedotin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RG-7304
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • taselisib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CH-5036249
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CH-5164840
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CH-5449302
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CH-5451098
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CVE-199
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ERY-974
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • maxacalcitol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NA-255
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Agonize PTHR1 for Hypoparathyroidism
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • gMSC-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Chugai Pharmaceutical Co., Ltd. - Pipeline Analysis
    • Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Target
    • Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration
    • Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type
    • Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action
  • Chugai Pharmaceutical Co., Ltd. - Recent Pipeline Updates
  • Chugai Pharmaceutical Co., Ltd. - Dormant Projects
  • Chugai Pharmaceutical Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • nitazoxanide
      • basimglurant
      • bevacizumab
      • hyaluronate sodium
      • NA-808
      • onartuzumab
      • orlistat
      • PA-799
      • parsatuzumab
      • pictilisib
      • RG-7167
      • sembragiline
      • tocilizumab
      • trastuzumab emtansine
  • Chugai Pharmaceutical Co., Ltd. - Company Statement
  • Chugai Pharmaceutical Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Chugai Pharmaceutical Co., Ltd., Key Information
  • Chugai Pharmaceutical Co., Ltd., Key Facts
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Indication, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016
  • Chugai Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • Chugai Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016
  • Chugai Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016
  • Chugai Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2016
  • Chugai Pharmaceutical Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Chugai Pharmaceutical Co., Ltd. - Phase III, 2016
  • Chugai Pharmaceutical Co., Ltd. - Phase II, 2016
  • Chugai Pharmaceutical Co., Ltd. - Phase I, 2016
  • Chugai Pharmaceutical Co., Ltd. - Preclinical, 2016
  • Chugai Pharmaceutical Co., Ltd. - Discovery, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Target, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016
  • Chugai Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2016
  • Chugai Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2016
  • Chugai Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2016
  • Chugai Pharmaceutical Co., Ltd., Other Locations
  • Chugai Pharmaceutical Co., Ltd., Subsidiaries

List of Figures

  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016
  • Chugai Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • Chugai Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016
  • Chugai Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top